Foundayo Is Here
Foundayo (orforglipron) received FDA approval on April 1, 2026, and became the first oral GLP-1 weight loss medication that can be taken at any time of day, with or without food, and without water restrictions. Developed by Eli Lilly, it's a non-peptide, small-molecule GLP-1 receptor agonist — structurally different from semaglutide and tirzepatide, which are peptide-based.
LillyDirect began shipping Foundayo on April 6, 2026, and the medication is also available through retail pharmacies and telehealth platforms. This article covers the complete prescribing and dosing details.
The Titration Schedule
Foundayo uses a gradual dose-escalation approach, with at least 30 days at each dose level before increasing. This slow titration is designed to minimize gastrointestinal side effects — the most common adverse events associated with GLP-1 medications.
| Step | Dose | Duration | Purpose |
|---|---|---|---|
| 1 | 0.8 mg daily | At least 30 days | Starting dose — body adjustment |
| 2 | 2.5 mg daily | At least 30 days | First escalation |
| 3 | 5.5 mg daily | At least 30 days | Intermediate dose |
| 4 | 9 mg daily | At least 30 days | Therapeutic range begins |
| 5 | 14.5 mg daily | At least 30 days | Higher therapeutic dose |
| 6 | 17.2 mg daily | Maintenance | Maximum approved dose |
The full titration from starting dose to maximum takes approximately 20 or more weeks. Not everyone will need or tolerate the maximum 17.2mg dose — many patients find effective weight loss at 9mg or 14.5mg. Your prescriber will adjust based on your response and tolerability.
How It Differs From the Wegovy Pill
Foundayo and the Wegovy pill (oral semaglutide) are both oral GLP-1 medications, but they work differently at the molecular level and have very different dosing requirements. The Wegovy pill requires an empty stomach, swallowing with no more than 4 ounces of plain water, and a 30-minute fast after taking it. These restrictions exist because oral semaglutide uses SNAC (sodium N-[8-(2-hydroxybenzoyl) amino] caprylate) absorption technology, which requires specific stomach conditions to work.
Foundayo has none of these restrictions. Because orforglipron is a small molecule (not a peptide), it's absorbed efficiently through the stomach lining without special enhancement technology. You can take it with your morning coffee, after a meal, or before bed — whatever fits your routine.
Clinical Trial Results
In the ATTAIN-1 Phase 3 trial, adults with obesity or overweight without diabetes who took Foundayo at the highest dose experienced an average weight loss of approximately 27 pounds (about 11%) over 72 weeks, compared to roughly 5 pounds with placebo. Weight loss was dose-dependent — higher doses produced greater average weight reduction. Approximately 5% of body weight was lost within the first 12 weeks at the starting doses.
Pricing by Dose
Eli Lilly has structured Foundayo pricing by dose level through LillyDirect, making the early months of treatment more affordable. Starting doses are priced at $149 per month, with costs increasing as the dose escalates — intermediate doses run approximately $199, and the maintenance dose reaches $299 per month. Through December 31, 2026, Lilly is offering promotional pricing for eligible self-pay patients.
Foundayo is also eligible for the Medicare GLP-1 Bridge program starting July 1, 2026, which provides coverage at a $50 monthly copay for qualifying Medicare Part D beneficiaries.
Who Can Prescribe Foundayo?
Any licensed healthcare provider authorized to prescribe medications in your state can prescribe Foundayo. This includes primary care physicians, internists, endocrinologists, obesity medicine specialists, nurse practitioners, and physician assistants. Telehealth providers can also prescribe Foundayo — it's not a controlled substance, so DEA telehealth prescribing restrictions don't apply.
Side Effects to Discuss With Your Provider
Foundayo's side effect profile is similar to other GLP-1 medications. The most common adverse events are gastrointestinal: nausea, diarrhea, vomiting, constipation, and decreased appetite. These are generally most pronounced during dose escalation and tend to improve as your body adjusts.
The FDA label includes a black box warning about the risk of thyroid C-cell tumors, consistent with other GLP-1 receptor agonists. Foundayo is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. In April 2026, the FDA also requested additional data from Eli Lilly regarding Foundayo's liver safety profile — the medication remains approved and available, but this is something to discuss with your prescriber.